Urticaria is one of the most common dermatosis. Some of them are refractory to conventional treatments. For those in which disease is mediated for IgE, omalizumab is a therapeutic alternative which results in significant clinical and quality of life improvement of patients.
In this article, we report the cases of three patients where treatment with omalizumab improved its basal pathology of chronic urticaria and/or angioedema
© 2001-2024 Fundación Dialnet · Todos los derechos reservados